Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light

• US 20090023130A1
• Filed: 08/13/2008
• Published: 01/22/2009
• Est. Priority Date: 02/28/2003
• Status: Abandoned Application

• Current Assignee: Caridianbct Biotechnologies LLC (Baxter International Inc.)
• Original Assignee: Caridianbct Biotechnologies LLC (Baxter International Inc.)
• Inventors: MARSCHNER, Suzanne, GOODRICH, Raymond P.
• Application Number:
  US12/190,854
• Publication Number:
  US 20090023130A1
• Time in Patent Office: Days
• US Class Current: 435/2
• CPC Class Codes: A61K 41/0042 Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
• CPC Class Codes: A61K 41/17 by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/0082 using chemical substances
• CPC Class Codes: A61L 2/0088 Liquid substances
• CPC Class Codes: A61L 2/08 Radiation
• CPC Class Codes: A61L 2/10 Ultraviolet radiation
• CPC Class Codes: A61L 2202/22 Blood or products thereof
• CPC Class Codes: A61M 1/0213 with isolated sections of the tube used as additive reservoirs
• CPC Class Codes: A61M 1/3681 by irradiation
• CPC Class Codes: A61M 1/3683 using photoactive agents

Abstract

This invention is directed toward a method of preventing the formation of bioactive substances in a pathogen inactivated blood component. The steps include illuminating the blood component with light at a sufficient energy so that an alloxazine photosensitizer present in the blood component may be photolyzed to inactivate any pathogens which may be present; preventing the formation of bioactive substances in the pathogen inactivated blood component; and storing the pathogen inactivated blood component.

Claims

1. A method of preventing the formation of bioactive substances in pathogen inactivated blood or blood component comprising the steps of;

illuminating the blood or blood component with light at a sufficient energy so that an alloxazine photosensitizer present in the blood or blood component may be photolyzed to inactivate any pathogens which may be present;

preventing the formation of bioactive substances in the pathogen inactivated blood or blood component; and

storing the pathogen inactivated blood or blood component.

2. The method of claim 1 wherein the alloxazine photosensitizer is riboflavin.

3. The method of claim 1 wherein the energy sufficient to photolyze the alloxazine photosensitizer in the blood or blood component is about 6.24 J/mL.

4. The method of claim 1 wherein the step of preventing the formation of bioactive substances further comprises the step of not increasing neutrophil priming in a recipient of the pathogen inactivated blood or blood component.

5. The method of claim 1 wherein the blood component is platelets.

6. The method of claim 1 wherein the blood component is red blood cells.

7. The method of claim 1 wherein the blood component is plasma.